Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells

Abstract

Background: Metastasis causes the most breast cancer-related deaths in women. Here, we investigated the antitumor effect of solid lipid nanoparticles (SLN-DTX) when used in the treatment of metastatic breast tumors using 4T1-bearing BALB/c mice. Results: Solid lipid nanoparticles (SLNs) were produced using the high-energy method. Compritol 888 ATO was selected as the lipid matrix, and Pluronic F127 and Span 80 as the surfactants to stabilize nanoparticle dispersion. The particles had high stability for at least 120 days. The SLNs' dispersion size was 128 nm, their polydispersity index (PDI) was 0.2, and they showed a negative zeta potential. SLNs had high docetaxel (DTX) entrapment efficiency (86%), 2% of drug loading and showed a controlled drug-release profile. The half-maximal inhibitory concentration (IC 50) of SLN-DTX against 4T1 cells was more than 100 times lower than that of free DTX after 24 h treatment. In the cellular uptake test, SLN-DTX was taken into the cells significantly more than free DTX. The accumulation in the G2-M phase was significantly higher in cells treated with SLN-DTX (73.7%) than in cells treated with free DTX (23.0%), which induced subsequent apoptosis. TEM analysis revealed that SLN-DTX internalization is mediated by endocytosis, and fluorescence microscopy showed DTX induced microtubule damage. In vivo studies showed that SLN-DTX compared to free docetaxel exhibited higher antitumor efficacy by reducing tumor volume (p < 0.0001) and also prevented spontaneous lung metastasis in 4T1 tumor-bearing mice. Histological studies of lungs confirmed that treatment with SLN-DTX was able to prevent tumor. IL-6 serum levels, ki-67 and BCL-2 expression were analyzed and showed a remarkably strong reduction when used in a combined treatment. Conclusions: These results indicate that DTX-loaded SLNs may be a promising carrier to treat breast cancer and in metastasis prevention.

Methylene blue associated with maghemite nanoparticles has antitumor activity in breast and ovarian carcinoma cell lines

“…2g and i, respectively). Adaptation to excessive ROS levels in cancer cells has been reported, suggesting they have a higher basal ROS level than normal cells (Kim et al 2019); therefore, treatments that elevate ROS levels break the redox homeostasis and causes cancer cell death, as we can see with MAGCIT-MB treatment (Rocha et al 2020). An antagonistic fact is, however, observed after treatment with free MB, in which toxicity levels were subjected to low rates of agents (Fig.…”

CENPL, ISG20L2, LSM4&nbsp;and MRPL3&nbsp;Are Four Novel Hub Genes Involved in Breast Cancer Development and Progression

“…The results of GSVA was in accordance with the GSEA results. Cell-cycle dysregulation is one of the hallmarks of cancer and several researches have reported that cell cycle disturbance is the most important mechanism for cancer occurrence and progression [65,66]. Given that the speci c function that novel four hub genes have in cell cycle regulation is unknown, additional research is required to investigate those mechanisms in breast cancer in vitro and in vivo.…”

Nanotechnology‐Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis

“…[261] Docetaxel-loaded SLNs (DTX-SLNs) were investigated in metastatic breast tumors in vitro using murine breast adenocarcinoma (4T1), human breast cancer (MCF7), and murine embryo fibroblast (NIH-3T3) cells and in vivo using 4T1-bearing BALB/c mice. [262] It has been reported that DTX-SLNs induce apoptosis and microtubule damage, and decrease IL-6 production, B-cell lymphoma 2 (BCL-2) and Ki-67 expression, and tumor cell proliferation, leading to the inhibition of tumor progression and prevention of lung metastasis. [262] In another study, PTX-loaded SLNs modified with Tyr-3octreotide (TOC), a known ligand for somatostatin receptors overexpressed in glioma, were used for antiangiogenic and Reproduced with permission.…”

“…[262] It has been reported that DTX-SLNs induce apoptosis and microtubule damage, and decrease IL-6 production, B-cell lymphoma 2 (BCL-2) and Ki-67 expression, and tumor cell proliferation, leading to the inhibition of tumor progression and prevention of lung metastasis. [262] In another study, PTX-loaded SLNs modified with Tyr-3octreotide (TOC), a known ligand for somatostatin receptors overexpressed in glioma, were used for antiangiogenic and Reproduced with permission. [264] Copyright 2019, The Royal Society of Chemistry.…”